- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Patent holdings for IPC class C07K 16/24
Total number of patents in this class: 6191
10-year publication summary
468
|
503
|
506
|
526
|
605
|
643
|
676
|
609
|
528
|
148
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Janssen Biotech, Inc. | 1347 |
221 |
Novartis AG | 11238 |
208 |
Abbvie Inc. | 1808 |
131 |
Amgen Inc. | 3779 |
108 |
Genentech, Inc. | 3742 |
104 |
Eli Lilly and Company | 3645 |
97 |
MedImmune Limited | 627 |
91 |
Regeneron Pharmaceuticals, Inc. | 3650 |
86 |
Immatics Biotechnologies GmbH | 1144 |
78 |
Sanofi | 3836 |
77 |
Ablynx N.V. | 377 |
70 |
ZymoGenetics, Inc. | 244 |
65 |
Chugai Seiyaku Kabushiki Kaisha | 1259 |
58 |
F. Hoffmann-La Roche AG | 7958 |
54 |
Hoffmann-La Roche Inc. | 3060 |
54 |
Boehringer Ingelheim International GmbH | 4629 |
50 |
Coherus Biosciences, Inc. | 172 |
50 |
Bristol-myers Squibb Company | 5080 |
46 |
The Regents of the University of California | 18943 |
45 |
National University of Singapore | 2228 |
45 |
Other owners | 4453 |